Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test aims to spot pancreatic cancer before It's too late

NCT ID NCT06388967

Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study is testing a new blood test called PANXEON that looks for tiny genetic particles (miRNAs) to detect pancreatic cancer early. Researchers will collect blood samples from 2,000 people—some with pancreatic cancer and some without—to see how accurate the test is. If it works, it could lead to a simple, noninvasive way to catch this deadly cancer sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PANXEON blood test (measures miRNAs in blood samples)
What this could lead to
If successful, this blood test could help doctors detect pancreatic cancer earlier, when it is more treatable, potentially improving survival rates.
What could go wrong
This is a validation study, not a treatment trial. The test may not be accurate enough for widespread use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Independent cohorts of individuals with and without pancreatic cancer (cases and controls, respectively)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition) * Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment. * Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls) Exclusion Criteria: * Lack of written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma Pancreatic cancer, adult pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic adenocarcinoma Pancreatic cancer Pancreatic cancer non-resectable Pancreatic cancer resectable Pancreatic cancer stage Pancreatic cancer stage 0 Pancreatic cancer stage I Pancreatic cancer stage II Pancreatic cancer stage III Pancreatic cancer, adult Pancreatic carcinoma Pancreatic ductal adenocarcinoma Pancreatic neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, South Korea

  • Atlantic Health System

    RECRUITING

    Morristown, New Jersey, 07960, United States

  • City of Hope Medical Center

    RECRUITING

    Monrovia, California, 91016, United States

  • Hoag Center

    RECRUITING

    Newport Beach, California, 92663, United States

  • Honorhealth

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Nagoya University

    RECRUITING

    Nagoya, Japan

  • OSF HealthCare

    RECRUITING

    Peoria, Illinois, 61637, United States

  • Ochsner Medical Center

    RECRUITING

    Jefferson, Louisiana, 70121, United States

  • Piedmont Medical Center

    RECRUITING

    Rock Hill, South Carolina, 29732, United States

  • Translational Genomics Research Institute

    RECRUITING

    Phoenix, Arizona, 85004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.